Danaparoid Sodium

2020 ◽  
Author(s):  
Keyword(s):  
Danaparoid Sodium

Danaparoid sodium

2021 ◽  
Vol 1839 (1) ◽  
pp. 102-102
Keyword(s):  
Danaparoid Sodium

Heparin-induced Thrombocytopenia: Towards Consensus

1998 ◽  
Vol 79 (01) ◽  
pp. 1-7 ◽  
Author(s):  
Theodore Warkentin ◽  
Beng Chong ◽  
Andreas Greinacher
Keyword(s):  
Adverse Reaction ◽  
Treatment Approach ◽  
Diagnostic Testing ◽  
Optimal Treatment ◽  
Drug Induced ◽  
Danaparoid Sodium ◽  
Heparin Induced Thrombocytopenia ◽  
Thrombin Inhibition ◽  
Common Drug ◽  
Thrombotic Complications

SummaryHeparin-induced thrombocytopenia (HIT) is a drug-induced, immunoglobulin-mediated thrombocytopenic disorder that is important for at least three reasons. First, it is a relatively common drug-induced immunohematologic adverse reaction. Second, it is frequently complicated by life- and limb-threatening thrombotic complications. And third, there remains uncertainty about the optimal treatment approach for these patients. Recently, there has emerged increasing consensus on such important issues as the frequency, pathogenesis, and diagnostic testing, which we will summarize here. Further, a greater appreciation of the activation of the coagulation pathways in this syndrome indicate a rationale to treatment approaches that emphasize thrombin inhibition (eg. danaparoid sodium; hirudin and its analogues).

scholarly journals Usefulness of Danaparoid sodium in patients with Heparin-induced thrombocytopenia after cardiac surgery

2015 ◽  
Vol 4 (2) ◽  
pp. 73 ◽  
Author(s):  
Fariborz Farsad ◽  
Farzaneh Foroughinia ◽  
Kheirollah Gholami ◽  
Somayeh Ahmadi
Keyword(s):  
Cardiac Surgery ◽  
Danaparoid Sodium ◽  
Heparin Induced Thrombocytopenia

scholarly journals A case of portal vein thrombosis following sepsis successfully treated with danaparoid sodium and endotoxin adsorption therapy

2009 ◽  
Vol 20 (3) ◽  
pp. 126-132
Author(s):  
Masaru Nagato ◽  
Kei Goto ◽  
Nobuya Harayama ◽  
Shun-ichi Nihei ◽  
Fumihiko Mouri ◽  
...  
Keyword(s):  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Danaparoid Sodium ◽  
Vein Thrombosis

Danaparoid sodium

2000 ◽  
Vol 1 (4) ◽  
pp. 803-814 ◽  
Author(s):  
Jose M Acostamadiedo ◽  
Uma G Iyer ◽  
John Owen
Keyword(s):  
Danaparoid Sodium

Danaparoid sodium reduces ischemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses

2007 ◽  
Vol 97 (01) ◽  
pp. 81-87 ◽  
Author(s):  
Naoaki Harada ◽  
Hidefumi Kohmura ◽  
Mitsuhiro Uchiba ◽  
Tsutomu Tomita ◽  
Kenji Okajima
Keyword(s):  
Liver Injury ◽  
Rat Model ◽  
Inflammatory Responses ◽  
Ischemia Reperfusion ◽  
Hepatic Tissue ◽  
Therapeutic Effects ◽  
Danaparoid Sodium ◽  
Cgrp Release ◽  
Neuron Activation

SummaryThis study was undertaken to examine the mechanism by which danaparoid sodium (DS), a heparinoid that contains mainly heparan sulfate, prevents reperfusion-induced hepatic damage in a rat model of ischemia/reperfusion (I/R)-induced liver injury. Administration of DS significantly reduced liver injury and inhibited the decrease in hepatic tissue blood flow in rats. DS attenuated hepatic I/R-induced increases in hepatic tissue levels of tumor necrosis factor (TNF) and myeloperoxidase (MPO) in vivo. In contrast, neither monocytic TNF production nor neutrophil activation was inhibited by DS in vitro. DS enhanced I/R-induced increases in levels of calcitonin-gene related peptide (CGRP), a neuropeptide released from sensory neurons, and of 6-ketoprostaglandin (PG) F1α, a stable metabolite of PGI2, in liver tissues. The therapeutic effects of DS were not seen in animals pretreated with capsazepine, an inhibitor of sensory neuron activation. The distribution of heparan sulfate in the perivascular area was significantly increased by DS administration in this rat model. DS significantly increased CGRP release from isolated rat dorsal root ganglion neurons (DRG) in vitro, while DX-9065a, a selective inhibitor of activated factor X, did not. DS enhanced anandamide-induced CGRP release from DRG in vitro. These observations strongly suggested that DS might reduce I/R-induced liver injury in rats by attenuating inflammatory responses. These therapeutic effects of DS might be at least partly explained by its enhancement of sensory neuron activation, leading to the increase the endothelial production of PGI2.

Prospective Randomised Open-label Comparison of Danaparoid with Dextran 70 in the Treatment of Heparin-induced Thrombocytopaenia with Thrombosis

2001 ◽  
Vol 86 (11) ◽  
pp. 1170-1175 ◽  
Author(s):  
B. H. Chong ◽  
J. F. Cade ◽  
H. Magnani ◽  
A. Manoharan ◽  
M. Oldmeadow ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Odds Ratio ◽  
Clinical Effectiveness ◽  
Serotonin Release ◽  
Thromboembolic Events ◽  
Open Label ◽  
Danaparoid Sodium ◽  
Clinical Recovery ◽  
Dextran 70 ◽  
Discharge From Hospital

Summary Aim: To compare clinical outcomes in a randomised comparison of treatment with danaparoid sodium (a heparinoid), or dextran 70, for heparin-induced thrombocytopaenia (HIT) plus thrombosis. Methods: Forty-two patients with recent thrombosis and a clinical diagnosis of probable HIT who presented at ten Australian hospitals during a study period of six and one half years were randomly assigned to open-label treatment with intravenous danaparoid or dextran 70, each combined with oral warfarin. Thirty-four patients (83%) had a positive platelet aggregation or 14C-serotonin release test for HIT antibody. Twenty-five received danaparoid as a bolus injection of 2400 anti-Xa units followed by 400 units per hour for 2 h, 300 units per hour for 2 h, and then 200 units per hour for five days. Seventeen received 1000 mL dextran 70 on day one and then 500 mL on days 2-5. Patients were reviewed daily for clinical evidence of thrombus progression or resolution, fresh thrombosis or embolism, bleeding or other complications. The primary trial endpoint was the proportion of thromboembolic events with complete clinical resolution by the time of discharge from hospital. Results: With danaparoid, there was complete clinical recovery from 56% of thromboembolic events compared to 14% after dextran 70 (Odds Ratio 10.53, 95% Confidence Interval 1.6–71.4; p = 0.02). Clinical recovery with danaparoid was complete or partial in 86% of thromboembolic events compared with 53% after dextran 70 (Odds Ratio 4.55, 95% Confidence Interval 1.2–16.7; p = 0.03). Overall clinical effectiveness of danaparoid was rated as high or moderate in 88% of patients compared with 47% for dextran 70 (p = 0.01). One patient given danaparoid died of thrombosis compared with three patients given dextran 70. The platelet count returned to normal after a mean of 6.7 days with danaparoid and 7.3 days with dextran 70. There was no major bleeding with either treatment. Conclusion: danaparoid plus warfarin treatment for HIT with thrombosis is effective, safe, and superior to dextran 70 plus warfarin.

Sign in / Sign up

Export Citation Format

Share Document